This inventor holds 2 USPTO granted patents. Top assignees: Abelzeta Inc., Cellular Biomedicine Group (Shanghai) Ltd., Cellular Biomedicine Group (Wuxi) Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 9 
1 out of 4 
1 out of 4 Years Active: 2026
Title: Wei Zhu: Innovator in Chimeric Antigen Receptor Technology
Introduction
Wei Zhu is a prominent inventor based in Rockville, MD (US). He has made significant contributions to the field of immunotherapy, particularly in the development of chimeric antigen receptors (CARs). His work focuses on enhancing the efficacy of engineered T cells in targeting specific antigens.
Latest Patents
Wei Zhu holds a patent titled "Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof." This patent represents a crucial advancement in the treatment of diseases such as certain types of cancer, where targeting CD20 can lead to improved therapeutic outcomes. He has 1 patent to his name.
Career Highlights
Wei Zhu is currently associated with Abelzeta Inc., where he continues to innovate in the field of CAR technology. His work is instrumental in developing therapies that harness the power of the immune system to fight cancer.
Collaborations
Wei Zhu collaborates with notable colleagues, including Yihong Yao and Jiaqi Huang. Their combined expertise contributes to the advancement of research and development in immunotherapy.
Conclusion
Wei Zhu's contributions to the field of chimeric antigen receptors are paving the way for new cancer therapies. His innovative work at Abelzeta Inc. and his collaborations with esteemed colleagues highlight his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile